Lupin has launched Clobetasol Propionate Lotion 0.05% having received an approval from the United States Food and Drug Administration (USFDA) earlier. Clobetasol Propionate Lotion 0.05% had annual sales of around $12.6 million in the US (IQVIA MAT December 2017).
Lupin’s Clobetasol Propionate Lotion 0.05% is the generic equivalent of Galderma Labs’ Clobex lotion. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, in patients 18 years of age or older.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
